AHASTAT blog: Reducing 340B is not the answer to curbing skyrocketing drug prices

Mar 08, 2016 - 04:28 PM

A recent proposal that calls for reducing the benefits of the 340B Drug Pricing Program to curb rapidly rising prescription drug costs is “misguided,” writes AHA Executive Vice President Tom Nickels in an AHASTAT blog post today. Responding to a recent opinion piece in the New England Journal of Medicine, Nickels said, “The 340B program is more important now than ever before as the prices of prescription drugs continue to skyrocket. Instead of trying to make changes to a program with a strong track record of increasing access to care for patients in vulnerable communities, policymakers should consider other solutions, such as requiring greater transparency on drug pricing and charity policies by drug companies, increased competition in the generic industry or other reasonable proposals.” For more on the 340B program, visit www.aha.org/protect340B.

Related News Articles

Headline
DEA, HHS extend telemedicine waivers through 2026
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
CMS proposes new drug pricing model to expand GLP-1 access to those with Medicare Part D and Medicaid
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
CMS releases proposed rules on two drug pricing models
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
Administration reaches deals with 9 drug companies to lower drug costs
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
CMS announces pilot on MA service level data collection for initial determinations, appeals
The Centers for Medicare & Medicaid Services released a memo Dec. 16 announcing the agency’s intent to conduct a voluntary pilot in 2026, called the…
Headline
Blog: Putting 340B Program Growth in Context
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…